Proceedings of the International scientific and practical conference ―New York Global Science Conference 2026‖ (May 18-20, 2026) / Publisher website: www.naukainfo.com. – New York, USA, 2026. - 322 p.

250 After the course of therapy (statins, aspirin, ACE inhibitors combined with β-AB or CCB), both groups showed a statistically significant decrease in HR (from 84.73 ± 2.00 to 78.23 ± 1.77 bpm, p<0.05), indicating normalisation of cardiac autonomic tone and reduction of sympathetic activity. The observed decrease in SBP (from 170.15 ± 1.05 to 151.70 ± 1.14 mmHg (↓10.8%), p<0.001) and DBP (from 89.63 ± 1.30 to 84.93 ± 0.94 mmHg (↓5.2%), p<0.01) confirms the effective antihypertensive action of the prescribed therapy. The achieved significant reduction in TC by 26.2% (from 5.99 ± 0.14 to 4.42 ± 0.11 mmol/l, p<0.001) and LDL by 28.3% (from 3.82 ± 0.11 to 2.74 ± 0.10 mmol/l, p<0.001), along with an increase in HDL by 61.7% (from 1.20 ± 0.05 to 1.94 ± 0.06 mmol/l, p<0.001), is a clinically significant result in the prevention of atherosclerotic lesions. The UA level showed a tendency toward a decrease of 5.3% (from 412.11 to 390.29 µmol/l, p>0.1), which also positively indicates a reduction in the risk of metabolic disorders and hyperuricaemia, and models a potential decrease in the risk of vascular inflammatory reactions, improvement of purine metabolism — possibly as an effect of blood pressure normalisation or drug influence. LVEF remained stable with a slight positive change (+0.53%, p>0.1), maintaining myocardial pump function at a stable level. Consequently, as a result of the treatment, patients demonstrated statistically significant positive changes in the main haemodynamic and metabolic parameters. Further analysis examined the effects of β-AB and CCB on clinical parameters separately. In the β-AB group, a notable decrease in HR (−13.2%, p<0.005) and a reduction in BP — particularly SBP (−7.3%, p<0.001) — were recorded, indicating an antihypertensive effect. An improvement in the lipid profile was demonstrated: TC decreased (−24.8%, p<0.001) and LDL decreased (−28.6%, p<0.001) simultaneously with an increase in HDL (+66.9%, p<0.001). A tendency toward a decrease in UA (−6.5%, p>0.1) was noted, suggesting a potentially positive vascular effect; however, LVEF increased only slightly (+0.7%, p>0.5). In the CCB group, a minor decrease in HR (−2.1%, p>0.5) was recorded, along with a reduction in BP — both SBP (−14.3%, p<0.001) and DBP (−6.3%, p<0.005)